Inpharma 1299 - 4 Aug 2001

■ Irbesartan is more effective than atenolol inreducing left ventricular (LV) mass in patients withhypertension and LV hypertrophy, say researchersfrom Sweden and the US.* This double-blind studyinvolved 115 patients who were randomised to receiveeither irbesartan 150 mg/day or atenolol 50 mg/day for48 weeks. Both treatments progressively reduced LVmass index, but the mean reduction from baseline wassignificantly greater in the irbesartan group at week 48(–26 vs –14.1 g/m2). The proportion of patients with anormalised LV mass was greater among irbesartanrecipients (47 vs 32%). BP reductions werecomparable in the 2 groups.* The study was sponsored in part by Bristol-Myers Squibb, US,and Sanofi-Synthelabo, France.

Malmqvist K, et al. Regression of left ventricular hypertrophy in humanhypertension with irbesartan. Journal of Hypertension 19: 1167-1176, Jun2001 800872253

1

Inpharma 4 Aug 2001 No. 12991173-8324/10/1299-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved